logo-loader
viewHumanigen, Inc.

Humanigen chosen by National Institute of Health's upcoming coronavirus clinical trial

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial.

Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’ (NIAID) Big Effect Trial (BET) in patients hospitalized with COVID-19.

Quick facts: Humanigen, Inc.

Price: 3.37 USD

OTCMKTS:HGEN
Market: OTCQB
Market Cap: $425.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Britvic PLC sees acceleration in at-home channel sales lead by Pepsi-MAX in...

Britvic PLC (OTCQX:BTVCF) (LON:BVIC) Director of Investor Relations Stephen Nightingale tells Proactive the manufacturer of soft drinks saw an increase at-home channel sales with its slew of trusted soft drinks, despite a months-wide lockdown in the UK. Nightingale says its carbonates...

11 hours, 33 minutes ago

2 min read